Sat Kartar LifeShare price, financial results, shareholding and management
- Market cap
- ₹222 cr
- Stock P/E
- 13.0peers 21.3
- Book value
- ₹42.9
- Price to book
- 3.29
- EV / operating profit
- 8.2
- Market cap to sales
- 1.11
- ROCE · FY26
- 37.1%
- ROE · FY26
- 28.6%
- ROE, 3-year average
- 49.5%
- Operating margin · FY26
- 12.3%peers 8.9%
- Sales growth, 3 years
- 34.2%
- Profit growth, 3 years
- 78.6%
- Debt to equity
- 0.04peers 0.48
- Borrowings
- ₹2.4 cr
- Interest cover
- 44.8×
- Cash from business / op. profit
- 2%
- Debtor days
- 26
- Pledged
- 0.00%
- Promoter holding
- 63.62%
- Change in promoter holding
- +0.19 pts
- Shareholders
- 846
- 52-week high / low
- ₹220 / ₹110
- Dividend yield
- Paid
- Face value
- ₹10
Tap or hover on any figure for what it means. Our arithmetic on reported figures, at the latest close.
Sat Kartar Life share price chart
Close on 6 Nov 2026 · +4.98% on the day · Vol 47,200
Daily prices to 6 Nov 2026, adjusted for splits and bonuses. Closing prices only: check the exchange for the live price.
Share price returns
To the close of 6 Nov 2026
- 1 month
- -11.6%
- 3 months
- +18.5%
- 6 months
- -29.8%
- 1 year
- -26.1%
- Since IPO
- +74.3%
- Traded a day, 20 days
- ₹0.64 cr
- Taken for delivery
- 69%
Business growth
Sales and net profit, from the reported results
| Sales | Profit | |
|---|---|---|
| FY26 on FY25 | +23% | +71% |
| 3 years, a year | +34% | +79% |
| Latest half, H2 FY26 | +21% | +58% |
About Sat Kartar Life: business, products and customers
Sat Kartar Life makes and markets Ayurvedic medicines for problems such as diabetes, piles, joint pain and quitting addictions, taking orders by phone from people all over India. It has also opened its first Ayurveda hospital in Delhi, and its shares trade on NSE Emerge.
Sat Kartar Life, earlier called Sat Kartar Shopping, offers Ayurvedic capsules, powders and oils straight to people at home. Buyers see an advertisement on television, Google, YouTube or Meta, call in, and speak to an advisor in their own language. Orders go out by private couriers and by India Post, which reaches villages that couriers do not.
Most products are made by contract manufacturers under the company's own formulas; the offer document names six such agreements. Since late 2025 the company also runs a small capsule and powder unit of its own, which it says will make no more than half of its capsules. Advertising takes about 40% of sales, the company told investors in May 2026.
Read more about the business
South India gave 57.6% of sales in FY26 and Tamil Nadu alone 22%. In March 2026 the company opened a 30 bed Ayurveda hospital, Sat Kartar Sanjeevan, in Delhi, and it has since started a United States subsidiary. It runs a lower priced nutraceutical range through its subsidiary Ajooni Life Sciences and a diabetes range through Plantomed.
From the offer document, the FY26 annual report, the November 2025 investor presentation and the May 2026 earnings call.
Read the deeper study ↓In its favour
- Sales have grown fast: 34% a year over three years.
- It earns a high return on the money it uses: ROCE 37% in FY26.
- It has little debt for its size: debt to equity 0.04.
- The promoters own a large part of the company: 63.62%.
- It paid a dividend in the past year.
To watch
- Whether the Delhi hospital reaches the ₹0.01 cr a day of revenue the company gives as its break-even level.
- The plan to reach 300 hospital beds by FY27, with sites in Tamil Nadu and Visakhapatnam under study as of May 2026.
- The company's goal of ₹300 cr of product sales in FY27.
- Sales from the United States subsidiary, which started operations in June 2026.
- Customers take longer to pay than before: 26 days in FY26, against 1 in FY22.
From the company's documents first, then the reported figures read by fixed rules, the same for every company. Facts, not a view on the shares.
Sat Kartar Life revenue and profit growth
Half-yearly results · Profit and lossSales have grown fast. Last year profit grew faster than sales, so the company kept more from each rupee of sales.
SME companies report every six months. In the latest half, sales were higher than in the same half a year before. Profit grew faster than sales.
Sat Kartar Life half-yearly results
SME companies report every six months · ₹ crore
| H2FY24 | H1FY25 | H2FY25 | H1FY26 | H2FY26 | |
|---|---|---|---|---|---|
| Sales | 75 | 76 | 87.13 | 88.35 | 105.49 |
| Expenses | 69 | 70 | 78.53 | 78.07 | 91.02 |
| Operating profit | 6 | 6 | 8.60 | 10.28 | 14.46 |
| OPM | 8.0% | 7.0% | 9.9% | 11.6% | 13.7% |
| Interest | 0 | 0 | 0.32 | 0.27 | 0.24 |
| Depreciation | 1 | 1 | 0.77 | 1.29 | 2.01 |
| Profit before tax | 5 | 5 | 8.05 | 10.58 | 12.76 |
| Net profit | 4 | 4 | 5.99 | 7.79 | 9.47 |
Sat Kartar Life profit and loss
Full years to March, FY22 to FY26 · ₹ crore, consolidated where reported
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Sales | 52 | 83 | 128 | 163 | 200.70 |
| Expenses | 49 | 78 | 118 | 149 | 176 |
| Operating profit | 3 | 5 | 10 | 14 | 24.69 |
| OPM | 5.0% | 6.0% | 8.0% | 9.0% | 12.3% |
| Other income | 0 | 0 | 0 | 1 | 2.42 |
| Interest | 0 | 0 | 1 | 1 | 0.53 |
| Depreciation | 1 | 1 | 1 | 1 | 3.37 |
| Exceptional and other items | · | -1 | 1 | · | · |
| Profit before tax | 2 | 3 | 9 | 13 | 23.22 |
| Tax rate | 50.0% | 0.0% | 33.3% | 23.1% | 26.4% |
| Net profit | 1 | 3 | 6 | 10 | 17.10 |
| EPS ₹ | 1.99 | 3.59 | 22.54 | 6.24 | 10.86 |
| Dividend payout | 0.0% | 0.0% | 3.0% | 11.0% | 6.0% |
The years to FY25 come rounded to the nearest crore in the source.
Exceptional and other items: profit before tax beyond operating profit, other income, interest and depreciation, such as one-off items or a share of associates' profit, as reported.
Sat Kartar Life profitability
Margins and returns on capitalLast year the company kept more from each rupee of sales than the year before. It earns a high return on the money it uses.
Operating margin, every year
Per cent of sales kept before interest, depreciation and tax
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Operating margin | 5.0% | 6.0% | 8.0% | 9.0% | 12.3% |
| Tax rate | 50.0% | 0.0% | 33.3% | 23.1% | 26.4% |
| ROCE | · | 36.6% | 101.5% | 40.0% | 37.1% |
| ROE | · | 136.4% | 87.6% | 32.3% | 28.6% |
| Dividend payout | 0.0% | 0.0% | 3.0% | 11.0% | 6.0% |
Sat Kartar Life debt and cash flow
Balance sheet · Cash flow · Working capitalThe company's own money, its net worth, has grown fast. It cut its borrowings last year. Its loans are smaller than its own money. Last year the business brought in less cash than it showed as profit, so part of the profit is still to be collected. It spent more on assets and investments than the business brought in, and drew on its cash. Customers take longer to pay than they did in FY24, which ties up more of the company's money in unpaid bills.
Bars below the line are cash going out.
Sat Kartar Life balance sheet
At each 31 March · ₹ crore
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Equity capital | 0.70 | 0.70 | 3 | 16 | 15.74 |
| Reserves | 0 | 3 | 7 | 36 | 51.85 |
| Net worth | 0.70 | 3.70 | 10 | 52 | 67.60 |
| Borrowings | 8 | 4 | 2 | 6 | 2.42 |
| Other liabilities | 3.30 | 7.30 | 10 | 7 | 14.83 |
| Total liabilities | 12 | 15 | 22 | 65 | 84.85 |
| Fixed assets | 5 | 4 | 8 | 6 | 11.22 |
| Capital work in progress | 0 | 0 | 0 | 0 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0.52 |
| Other assets | 7 | 11 | 14 | 59 | 72.11 |
| Receivables | · | · | · | · | 14.47 |
| Inventory | · | · | · | · | 10.48 |
| Cash | · | · | · | · | 21.86 |
| Trade payables | · | · | · | · | 11.81 |
Sat Kartar Life cash flow
₹ crore
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Cash from operations | · | · | 7 | -5 | 0.48 |
| Cash from investing | · | · | -3 | 0 | -8.55 |
| Cash from financing | · | · | -3 | 34 | -0.77 |
| Net cash flow | · | · | 1 | 29 | -8.84 |
| Capital spending | · | · | · | · | 10.16 |
Working capital
Days
| FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|
| Debtor days | 1 | 0 | 7 | 13 | 26 |
| Inventory days | 31 | 25 | 23 | 185 | 264 |
| Days payable | 165 | 226 | 237 | 170 | 298 |
| Cash conversion cycle | -134 | -200 | -208 | 29 | -7 |
| Working capital days | 1 | -14 | -7 | 31 | 58 |
Sat Kartar Life peers and competitors
Listed SME companies in the same industryBy sales, Sat Kartar Life is number 3 of the 34 listed SME companies in pharmaceuticals & biotechnology.
Each company's latest full year and its latest close; companies the exchange puts in the same industry, whose businesses can differ a good deal. A list, not a comparison of their shares.
| Company | Market cap ₹ cr | P/E | Sales ₹ cr | Profit ₹ cr | Op. margin | Debt/equity |
|---|---|---|---|---|---|---|
| Sat Kartar Life | 222 | 13.0 | 201 | 17.1 | 12.3% | 0.04 |
| Infinium Pharmachem | 471 | 38.7 | 190 | 12.2 | 11.4% | 0.19 |
| Zenith Drugs | 68 | 17.2 | 171 | 3.9 | 7.1% | 0.75 |
| Mono Pharmacare | 16 | 44.6 | 166 | 0.4 | 2.4% | 1.79 |
| Astonea Labs | 341 | 68.1 | 148 | 5 | 9.0% | 0.74 |
| Influx Healthtech | 632 | 30.8 | 147 | 20.5 | 20.3% | 0.00 |
| Jfl Life Sciences | 35 | 5.5 | 131 | 6.4 | 8.9% | 0.47 |
| Dipna Pharmachem | 11 | 3.5 | 129 | 3 | 3.9% | 0.21 |
| Trident Lifeline | 481 | 25.3 | 129 | 19 | 22.0% | 0.73 |
| Chandra Bhagat Pharma | 32 | 10.5 | 116 | 3 | 3.3% | 0.50 |
| Quest Laboratories | 154 | 10.3 | 112 | 15 | 16.3% | 0.08 |
| Median of the 10 others | 111 | 21.3 | 139 | 5.7 | 8.9% | 0.48 |
Sat Kartar Life shareholding pattern
Promoters, FIIs, DIIs, HNIs and small holdersThe promoters own more than half the company. Big foreign and Indian funds own very little. The number of shareholders has come down.
Sat Kartar Life shareholding pattern
Per cent of shares, from the patterns filed with the exchange. Tap + to see everyone holding 1% or more in that group. HNIs and small holders show only where the pattern was filed in full.
| Jan 25 | Mar 25 | Sep 25 | Mar 26 | |
|---|---|---|---|---|
| Promoters | 63.31% | 63.34% | 63.43% | 63.62% |
| Foreign investors (FIIs) | 6.76% | 6.31% | 0.44% | 0.13% |
| Indian institutions (DIIs) | 5.48% | 3.70% | 3.10% | 2.26% |
| HNIs (over ₹2 lakh each) | 7.27% | 10.92% | 14.66% | 16.80% |
| Small holders (up to ₹2 lakh) | 11.96% | 6.88% | 9.76% | 10.49% |
| Companies and others | 5.22% | 8.85% | 8.61% | 6.70% |
| Number of shareholders | 1,311 | 425 | 717 | 846 |
The named holders are at 31 March 2026, beside 30 Sept 2025, each under the group the pattern files them in.
Sat Kartar Life study: the business from its own documents
Read from 14 of the company's own documentsSat Kartar Life so far
From the company's own record
- June 2012Company formed
- 17 Jan 2025Listed on NSE Emerge at ₹81
- 31 March 2026Promoters at 63.62%
- 30 Sept 2026Highest close since listing, ₹194.10
Sat Kartar Life key facts from the filings
Each figure with the document it comes from
- Sales in FY26
- ₹200.7 cr
- Up 23.2% on the year before, with profit of ₹17.1 cr.Press release, May 2026, p.2
- Spent on advertising
- About 40% of sales
- Every sale is won through fresh advertising; none of it is carried on the balance sheet.Earnings call transcript, May 2026, p.5
- Average order
- ₹3,250+
- Up from about ₹3,100 at the time of listing, the company says.Earnings call transcript, May 2026, p.8
- Repeat customers
- 25% to 26%
- About one customer in four orders again.Earnings call transcript, May 2026, p.8
- Sales from South India
- 57.6%
- Tamil Nadu alone gave 22% of FY26 sales.Annual report FY26, p.20
Show 5 more facts
- First hospital
- 30 beds
- Opened in Delhi in March 2026; under 10% of beds were in use about forty days later.Earnings call transcript, May 2026, p.3 and p.9
- Money raised in 2026
- ₹48.6 cr
- Raised from institutional investors and wealthy individuals for the hospital plan.Press release, May 2026, p.3
- Contract manufacturers
- 6
- Most products are made by partners under formulas the company controls.Offer document, p.141
- Customer database
- 30 million+
- Names gathered from enquiries, with about 25,000 new leads a day.Investor presentation, November 2025, p.7 and p.12
- Pincodes served
- 11,600+
- Deliveries reach places where online shopping does not.Investor presentation, November 2025, p.10
What the company said, and what happened
The company's own statements, attributed, set against what it later reported; not newboard's estimates
The company says it aims for product sales of ₹300 cr in FY27 and ₹500 cr in FY28, not counting hospitals, and plans to grow from 30 to 300 hospital beds by FY27, in facilities of 50 to 100 beds each. It says the first hospital breaks even at about ₹0.01 cr of revenue a day and was at about half that in May 2026. It expects more than ₹100 cr of hospital revenue by FY28 and has a non-exclusive collaboration with Jeena Sikho Lifecare, under which it takes a revenue share on patients it sends to Jeena Sikho centres.
| What management said | When | What happened |
|---|---|---|
| Revenue of ₹200 cr plus in FY26 | Nov 2025 call | ₹200.7 cr |
| PAT margin of 9% to 10% for FY26 | Nov 2025 call | 8.5% |
| No plan to raise equity; hospitals funded from internal accruals | Nov 2025 call | ₹48.6 cr raised by May 2026 |
| First 30 bed hospital in the first quarter of 2027 | Nov 2025 call | Opened March 2026 |
Is it a good business? Six questions
Each answer is about that one question, read from the documents; tap one for the evidence. Not a view on the shares.
Sat Kartar Life earns by advertising Ayurvedic remedies and turning callers into customers through a large team of advisors who speak their language.
Its weak spot is that every sale costs a lot of advertising, and the new hospital business is still early and not yet paying its way.
AverageCan it set its own prices?The average order has crept up, but the company needs heavy advertising to win each sale.
AverageHow strong is it against rivals?Its edge is a multilingual call centre and delivery deep into rural India, but Ayurvedic formulas cannot be owned.
StrongWho are its customers?Many individual people across India, with no single large customer; sales lean towards the South.
WatchDoes it need a lot of money?The product business needs little equipment, but the hospital plan needs fresh money for beds and working capital.
AverageCan it keep finding new work?There is no order book; each month's sales come from that month's advertising and the leads it brings.
AverageDo good and bad years swing a lot?Sales have grown each year, but outside events such as a slowdown or a delivery partner's problems can hit a half year.
Who runs Sat Kartar Life?
Promoters, directors and officers; tap a name for the background
MSManprit Singh ChadhaPromoter, Founder and Chief Operating Officer · holds 23.64%
A chartered accountant (1994) and Delhi University commerce graduate with more than 30 years of work in biotechnology, telecom, automobiles and customer support operations. Earlier roles include Financial Controller at Daksh e-services, Business Support Head at Watson Towers and CFO at Bharti Telecom (Airtel) in Seychelles and at Pan India Motors. Founded the company and speaks for it on earnings calls.
Offer document, p.214; Annual report FY26, p.24AWAjooni Wellness Private LimitedCorporate promoter · holds 36.28%
Incorporated in March 2023; Manprit Singh Chadha held 9,997 of its 10,000 shares at the offer. The company says it runs no business and only holds Sat Kartar Life shares.
Offer document, p.216 to 217; Earnings call transcript, May 2026, p.5VPVed PrakashManaging Director
A Delhi University commerce graduate with over 12 years in marketing Ayurveda products. Was with the company at its start, worked freelance from 2013 to 2018, returned in 2018 to run marketing, and became Managing Director on 1 May 2024.
Offer document, p.198PSPranav Singh ChadhaPromoter and Executive Director
A commerce graduate of Sri Guru Gobind Singh College of Commerce. Joined the company in 2017 as a digital marketing associate, worked at ODN Digital Services as Senior Manager, Client Success from October 2021 to October 2023 on campaigns for brands such as Zydus Wellness, CRED and Flipkart, then returned.
Offer document, p.198 and p.215SKSimrati KaurPromoter and Executive Director
A B.Tech in computer science from Indira Gandhi Institute of Technology with four years in digital marketing at the offer, leading product launches, content and marketing campaigns.
Offer document, p.198 and p.215 to 216SKSanjay KumarExecutive Director
A Delhi University arts graduate with over 20 years in administration, procurement, logistics, supply chain and compliance. Earlier worked at Agilent Technologies, Contentra Technologies and Seven Colours Exim. Executive Director since January 2021.
Offer document, p.199RTRicha TakkarNon-Executive Director
A Delhi University arts graduate with six years in customer support at the offer, rising from team leader to director.
Offer document, p.199MKManoj Kumar VermaIndependent Director
A company secretary in practice for 15 years under Manoj Verma & Associates, with over 32 years in corporate law at the offer. Chairs the nomination and remuneration committee.
Offer document, p.199; Annual report FY26, p.27Sat Kartar Life latest news and announcements
Announcements · Documents · Corporate actionsWhat changed recently
Each half-year is set against the same half a year earlier
- H2 FY26: sales ₹105 cr (+21%), net profit ₹9.5 cr (+58%) on H2 FY25.
- Shareholding, 31 March 2026: promoters 63.43% to 63.62%; Aarth AIF Growth Fund no longer named at 1% or more (was 1.33%).
Sat Kartar Life announcements
185 on record, latest first; each opens the filing on the exchange
- Quarterly Compliance Report on Corporate governance - within 21 days from the enNon-Applicability of Regulation 27(2) of the Securities Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations, 2015 for the QuartPDF ↗
- Certificate under SEBI (Depositories and Participants) Regulations, 2018about Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026PDF ↗
- Copy of Newspaper PublicationRegarding completion of dispatch of EGM Notice and Intimation of remote evoting facility and Meeting through Video Conferencing / Other Audio Visual MeansPDF ↗
- Shareholders meetingNotice of Extraordinary General Meeting to be held on October 23, 2026PDF ↗
- Issue of SecuritiesIssuance of the Convertible Warrants by way of Preferential IssuePDF ↗
- Outcome of Board MeetingHeld on September 30, 2026PDF ↗
- Trading WindowClosure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015PDF ↗
- Capacity additionProposal for Establishment of new hospital -cum-therapy center in Dehradun, UttarakhandPDF ↗
- Analysts/Institutional Investor Meet/Con. Call UpdatesSchedule of meetPDF ↗
- AppointmentRe- appointment of M/s. Nidhi Bansal & Co. as Statutory Auditor of the CompanyPDF ↗
- Shareholders meetingSrutinizers report of Annual General Meeting held on August 28, 2026. Further, the company has informed the Exchange regarding voting resultsPDF ↗
- Shareholders meetingProceedings of Annual General Meeting held on August 28, 2026PDF ↗
Sat Kartar Life annual reports, earnings calls and documents
Every document links to its source; “read” marks those this page is built from
- Offer document ↗read
- 15 May 2025 ↗read
Sat Kartar Life share split, bonus and dividends
From the corporate actions the company announces on the exchange
- DividendDIVIDEND - RE 0.70 PER SHAREex-date 21 Aug 2026
- DividendDIVIDEND - RE 0.70 PER SHAREex-date 22 Aug 2025
Checks we ran on Sat Kartar Life's data · 9
Before any number shows, it goes through the same checks. A figure that fails is held back, never shown as if it were right.
- ✓Balance sheet totals add up for FY25 and FY26.
- ✓Market cap uses the share count in the latest shareholding pattern (1,57,44,876 shares).
- ✓The share capital in the FY26 results matches the share count in the shareholding pattern.
- ✓Promoter pledge figures are within possible limits in every shareholding pattern shown.
- ✓Promoter and public holdings add up to 100% in every shareholding pattern shown.
- !The two half-years of FY26 add up to ₹193.8 cr of sales against ₹200.7 cr for the full year; both are shown as reported.
- !Earnings per share changes basis between FY23 (₹3.59) and FY24 (₹22.54) because the share count behind it changes; EPS is shown as reported, and growth is worked out on profit.
- ✓Revenue and profit are reported for every year shown, FY22 to FY26.
- iPrices run to the close on 14 Oct 2026, from the exchange's daily figures.
Questions people ask about Sat Kartar Life
What does Sat Kartar Life do?
Sat Kartar Life makes and markets Ayurvedic medicines for problems such as diabetes, piles, joint pain and quitting addictions, taking orders by phone from people all over India. It has also opened its first Ayurveda hospital in Delhi, and its shares trade on NSE Emerge.
What is the share price of Sat Kartar Life?
₹141 at the close on 6 Nov 2026, from the exchange's daily figures.
What is the market cap of Sat Kartar Life?
₹222 cr at the close on 6 Nov 2026, on 1,57,44,876 shares.
What is the P/E of Sat Kartar Life?
13.0 times FY26 profit at the close on 6 Nov 2026 (our arithmetic).
What are Sat Kartar Life's revenue and profit?
Revenue ₹201 cr and profit after tax ₹17 cr in FY26.
Who are the promoters of Sat Kartar Life?
Manprit Singh Chadha, Ajooni Wellness Private Limited, Pranav Singh Chadha, Simrati Kaur; promoters held 63.62% at 31 March 2026.
What was the IPO price of Sat Kartar Life?
₹81 a share; it listed on 17 Jan 2025.
What is Sat Kartar Life's website?
www.satkartar.in
More SME companies like Sat Kartar Life
Other listed SME companies in pharmaceuticals & biotechnology, the closest in size first, each read from its own documents.
- Accretion PharmaceuticalsACCPL · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2025Market cap ₹227 cr
- Accretion NutravedaANL · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹244 cr
- Bio Medica LaboratoriesBMLL · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2026Market cap ₹182 cr
- Quest LaboratoriesQUESTLAB · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2024Market cap ₹146 cr
- Sotac PharmaceuticalsSOTAC · NSE Emerge · Pharmaceuticals & Biotechnology · listed 2023Market cap ₹143 cr
- Speciality MedicinesSPML · BSE SME · Pharmaceuticals & BiotechnologyMarket cap ₹136 cr
Every listed SME company in Pharmaceuticals & Biotechnology → · SME companies listed in 2025 →
Built from 3 earnings call transcripts, 3 investor presentations, 3 press releases, 2 annual reports, 1 offer document, 1 result filing, 1 credit rating note, 185 exchange announcements, 4 shareholding patterns and 5 years of reported results. Every figure carries its source; where the documents are silent, the page says so.